Dr. Terence A. Kelly is a seasoned pharmaceutical executive with over 30 years of experience in drug discovery and development across the U.S. and Europe. He began his career in 1990 as a medicinal chemist at Boehringer Ingelheim, contributing to projects in Immunology, Virology, CNS, and Cardiovascular diseases. From 2002 to 2009, he led the company's U.S. medicinal chemistry department, overseeing 145 scientists across various disciplines. In 2010, Dr. Kelly joined the neuroscience company CoMentis as Chief Scientific Officer, later becoming President and CEO. From 2019 to 2023 he served as President and CEO of Perception Neuroscience, a clinical-stage biotech company focused on mental health disorders. Dr. Kelly holds a B.S. in Chemistry from Rensselaer Polytechnic Institute, a Ph.D. in Chemistry from the University of Texas at Austin, and an MBA from New York University's Stern School of Business. He completed postdoctoral research in natural product synthesis at Yale University. Throughout his career, he has co-authored over 25 scientific publications and is an inventor on multiple patents. Currently, Dr. Kelly is the founder and President of Kelly Pharma Research Consulting, LLC, providing strategic and practical solutions in the drug discovery space. Dr. Kelly brings invaluable expertise to our team in advancing innovative healthcare solutions.

Professor Alexander Knuth, MD, is a medical oncologist and cancer immunologist with a distinguished career spanning several decades. He earned his medical degree from the Free University of Berlin in 1973 and completed his doctorate in pathology at the University of Zurich in 1974. His pioneering work in cancer immunology led to the discovery of multiple human cancer antigens, including MAGE, the first identified cancer/testis antigen, which has been a primary target in cancer vaccine development. From 2003 to 2013, Professor Knuth served as the Chair of Internal Medicine/Oncology at the University of Zurich, Switzerland. Following this, he was appointed as the Chief Executive Officer and Medical Director of the National Center for Cancer Care and Research at Hamad Medical Corporation in Doha, Qatar, a position he held until 2020. Throughout his career, Professor Knuth has been dedicated to advancing cancer immunotherapy, focusing on the development of peptide-based vaccines and adjuvants, establishing immune-monitoring techniques, and uncovering tumor escape mechanisms. His contributions have been recognized with numerous awards, including the prestigious Johann-Georg-Zimmermann Medal. Currently, as Professor Emeritus at the University of Zurich, Professor Knuth continues to contribute to the field of oncology through research and mentorship. His extensive clinical experience and groundbreaking research in cancer immunology make him an invaluable member of our team, guiding our efforts to develop innovative cancer therapies.

Professor Michael Scharl, MD, is a distinguished gastroenterologist and researcher at the Department of Gastroenterology and Hepatology of the University Hospital Zurich, where he currently holds the position of Senior Attending Physician, heads the Translational Microbiome Research Center and acts as Vice Director of the Department. He is also Associate Professor for Gastroenterology and Hepatology with focus on Translational Microbiome Research at the University of Zurich. Professor Scharl's research focuses on understanding the complex interplay between genetic predispositions, intestinal microbiota, and immune responses in the development of intestinal inflammation, colorectal carcinoma and other malignancies. His work ultimately aims to improve the therapeutic options and quality of life of patients with gastrointestinal diseases. In recognition of his contributions to medical science, Professor Scharl has received multiple awards and is considered a leading expert in his field.